BigBear Communications was asked to act as interim Marketing Director and to oversee the launch of a new class of drug for the treatment of angina

Developing launch plans for their new guanosine cyclase stimulant for the treatment of Irritable Bowel Syndrome

BigBear Communications was called in to provide global strategic and commercial input into the early phase development of two intranasal products in the field of CNS Medicine.BigBear Communications was also called in to oversee the market research and competitive intelligence programmes for a third intranasal product with an application in oncology.

BigBear Communications was called in to prepare and implement the UK launch of a novel low molecular weight heparin.

BigBear Communications was asked to develop new global positioning for its lead brand and to develop global strategies for its promotion to healthcare professionals and specialists in the field of rheumatology

BigBear Communications was asked to act as Interim GI Divisional Head and to reskill the sales team to meet with new structure of the NHS in the UK. During this time, BigBear Communications sourced and launched a companion diagnostic for the detection of calprotectin. The objective was to create market access opportunities in the new payor organisations.

BigBear Communications was called in by this Venture Capital house to provide strategic support to one of its vested companies that was developing a novel medical device in the field of Intensive Care Medicine.

BigBear Communications was called in to provide a commercial assessment of a vested company and to propose further investment

Developing strategic workshops in support of their branded growth hormone

BigBear Communications was called in to work on preparing the European launch plan for a product to treat post-operative nausea and vomiting.

BigBear Communications was asked to help in the establishment of this Swiss company's UK affiliate, to establish the marketing systems and practices, launch three new products and to hire and train a permanent sales force

BigBear Communications was called in to advise this Japanese conglomerate on introducing its pharmaceutical portfolio into the European market. Conducted projects on a new drug for uraemic pruritus and overactive bladder